Table 1.
No. | Median (range) | |
---|---|---|
Age (years) | 54 (39–78) | |
Sex: Male/female | 15 / 8 | |
Race: Caucasian/Blacks | 18 / 5 | |
Isotype: Ig G/A/LC | 11 / 4 / 8 | |
No of Prior Regimens | 7 (3–13) | |
SCT-Autologous/Tandem/Allo | 20 / 6/ 1 | |
Prior Thalidomide / Lenalidomide | 23 / 17 | |
Bortezomib | 19 | |
Duration (months) | 6 (2–40) | |
No. of regimens 1/2/3 | 8 / 5 / 6 | |
Primary refractory | 9 | |
Responsive then progressive | 10 | |
ECOG | 1 (0–2) | |
Time from diagnosis to study (years) | 5.7 (1.8 – 9) | |
Time from last therapy (days) | 20 (15 –39) | |
Creatinine (mg/dl) | 1.3 (0.7 – 2.1) | |
Hgb (g/dl) | 11 (8.5 – 14) | |
Platelets (×103/ul) | 148 (62 – 253) | |
Albumin (g/dl) | 3.8 (2.5 –4.7) | |
LDH (Units/L) | 209 (104 – 619) | |
Beta-2-microglobulin (mg/L) | 3 (1.3 – 6) | |
Baseline Peripheral neuropathy | 13 | |
Grade 1 / 2 | 11 / 2 | |
Abnormal karyotype | 14 | |
11;14 | 6 | |
Hypodeploidy: del(13), del(17) | 7/3 | |
Dup, der, del(1) | 9 | |